These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35364798)

  • 1. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
    Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
    Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
    Hua G; Carlson D; Starr JR
    J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
    N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
    Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
    Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
    J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tebentafusp in first-line melanoma trials: An outperforming outlier.
    Olivier T; Prasad V
    Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
    Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
    Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
    Damato BE; Dukes J; Goodall H; Carvajal RD
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
    Reschke R; Enk AH; Hassel JC
    Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
    Howlett S; Carter TJ; Shaw HM; Nathan PD
    Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
    Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
    Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GP100 expression is variable in intensity in melanoma.
    Mann JE; Hasson N; Su DG; Adeniran AJ; Smalley KSM; Djureinovic D; Jilaveanu LB; Schoenfeld DA; Kluger HM
    Cancer Immunol Immunother; 2024 Aug; 73(10):191. PubMed ID: 39105816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
    Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
    Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.